<DOC>
	<DOCNO>NCT03074162</DOCNO>
	<brief_summary>The main objective study assess relative systemic bioavailability diclofenacin presence absence capsaicin compare systemic bioavailability diclofenac combination product ( Diclofenac 2 % + Capsaicin 0.075 % Topical Gel ) two diclofenac product , Diclofenac Mono Gel 2 % VoltarolÂ® 12 Hour Emulgel 2.32 % Gel , follow topical administration . In order examine potential racial difference pharmacokinetics ( PK ) , study population stratify 50:50 , Caucasian versus Black people . With respect main objective , additionally supportive analysis perform investigate influence race intra-individual bioavailability ratio .</brief_summary>
	<brief_title>Comparison Bioavailability Diclofenac Diclofenac+Capsaicin Combination Gel Reference Product Diclofenac Gel Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Diclofenac</mesh_term>
	<mesh_term>Capsaicin</mesh_term>
	<criteria>Healthy male female , 18 50 year ( inclusive ) time screen . Body mass index ( BMI ) 18.5 29.9 kg/m2 ( inclusive ) . Body mass le 50 kg male female . Findings medical history , vital sign , physical examination , standard 12lead electrocardiogram ( ECG ) laboratory investigation must normal within laboratory reference range relevant laboratory test , unless PI considers deviation clinically significant purpose study . Nonsmokers . Females , : Not childbearing potential , Of childbearing potential , follow condition meet : Negative pregnancy test . Not lactate . Abstaining sexual activity ( usual lifestyle subject ) must agree use accepted method contraception , agree continue method throughout study . Written informed consent give participation study . Further inclusion criterion apply . Evidence psychiatric disorder , antagonistic personality , poor motivation , emotional intellectual problem likely limit validity consent participate study limit ability comply protocol requirement . Current alcohol use &gt; 21 unit alcohol per week male &gt; 14 unit alcohol per week female . One unit ( 10 g alcohol ) equal beer ( 330 mL ) , wine ( 200 mL ) , distilled spirit ( 25 mL ) per day . Regular exposure substance abuse ( alcohol ) within past year . Use medication , prescribe overthecounter ( especially product contain diclofenac use oral nonsteroidal antiinflammatory drug [ NSAIDS ] ) herbal remedy , within 2 week first administration IMP ( Investigational medicinal product ) except affect outcome study opinion PI ( Principal Investigator ) ( collaboration Sponsor ) . In study concomitant use hormonal contraceptive allow . Participation another study experimental drug , last administration previous IMP within 8 week ( within 5 elimination halflives chemical entity 2 elimination halflives antibody insulin ) , wichever long administration IMP study , discretion PI . Treatment within previous 3 month first administration IMP drug welldefined potential adversely affect major organ system . A major illness 3 month commencement screening period . History hypersensitivity allergy ( acute rhinitis , angioedema , urticaria bronchial asthma ) IMP excipients related medication ( Aspirin NSAID ) . History hypersensitivity allergy cayenne pepper capsaicinoids ( paprika plant ) . History bronchospasm bronchial asthma , arterial hypertension , myocardial infarction , thrombotic event , stroke , congestive heart failure , impaired renal function liver disease . History current diagnosis gastrointestinal bleeding peptic ulcer disease . Relevant history laboratory clinical finding indicative acute chronic disease , likely influence study outcome . Donation loss blood equal exceed 500 mL 8 week first administration IMP ( Investigational medicinal product ) . Bruises , damage skin , eczema wound application site , application site inappropriate apply IMP opinion PI ( Principal Investigator ) . Further exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>